Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
|Articles|April 21, 2015
Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer
Primo Neary Lara Jr., associate director of Translational Research at the UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Primo Neary Lara Jr., associate director of Translational Research and co-leader of the Cancer Therapeutics Program at UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Related to this article
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.
Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.
Advertisement
Advertisement